Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 2/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | XDH | P47989 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3566353 | 0.94 | CYP2A6 (0.61) | PTPN11LCKCA1CA2CA12 | |
| SCHEMBL29365729 | 0.92 | PTPN11 (0.68) | PTPN11LCKCA1CA2CA12 | |
| SCHEMBL69025 | 0.92 | PTPN11 (0.68) | PTPN11LCKCA1CA2CA12 | |
| SCHEMBL8732524 | 0.90 | PTPN11 (0.66) | PTPN11LCKCA1CA2CA12 | |
| SCHEMBL9979782 | 0.88 | PTPN11 (0.64) | PTPN11LCKCA1CA2CA12 | |
| SCHEMBL709231 | 0.85 | LCK (0.62) | PTPN11LCKCA1CA2CA12 | |
| SCHEMBL834744 | 0.85 | CYP2A6 (0.68) | LCKCA2CYP2A6ALDH1A1MAPT | |
| SCHEMBL262969 | 0.85 | PTPN11 (0.57) | PTPN11LCKCA1CA2CA12 | |
| SCHEMBL7744907 | 0.84 | PTPN11 (0.65) | PTPN11LCKCA1CA2CA12 | |
| SCHEMBL13900228 | 0.84 | CYP11B1 (0.69) | PTPN11LCKCA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230195003-A1 | ELECTROPHOTOGRAPHIC PHOTORECEPTOR, PROCESS CARTRIDGE, AND IMAGE FORMING APPARATUS | FUJIFILM BUSINESS INNOVATION CORP. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230195003-A1 | ELECTROPHOTOGRAPHIC PHOTORECEPTOR, PROCESS CARTRIDGE, AND IMAGE FORMING APPARATUS | FUJIFILM BUSINESS INNOVATION CORP. (JP) | 2023-06-22 | — | — | US | disclosed |
| CN-113842665-A | Leaching tower, system and method for purifying ester compounds | 中国石油化工股份有限公司 | 2021-12-28 | — | — | CN | disclosed |
| US-20170202795-A1 | SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY | H LEE MOFFITT CANCER CT & RES (US) | 2017-07-20 | — | — | US | disclosed |
| US-9630922-B2 | 3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9604923-B2 | Small molecule inhibitors of STAT3 with anti-tumor activity | H.LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160304462-A1 | 3-SPIRO-7-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | Valo Health, LLC | 2016-10-20 | — | — | US | disclosed |
| US-20140329900-A1 | SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8454940-B2 | Mixtures comprising benzotriazoles and merocyanines | BASF SE (DE) | 2013-06-04 | — | — | US | disclosed |
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
| EP-2091944-B1 | SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20100267769-A1 | Substituted Bicyclocarboxyamide Compounds | Pfizer, Inc. and Renovis Inc. | 2010-10-21 | — | — | US | disclosed |
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| EP-2091944-A2 | SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS | Pfizer, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-2044018-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS | Pfizer Japan, Inc. (JP) | 2009-04-08 | — | — | EP | disclosed |
| EP-2024272-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008059370-A2 | SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008007211-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007133637-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070031759-A1 | Radiation curable polymer films having improved laser ablation properties and radiation curable sensitizers therefor | NDSU RESEARCH FOUNDATION | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267769-A1 | Substituted Bicyclocarboxyamide Compounds | TRPV1, OPRL1, CNR1 | PTPN11 4176/4885LCK 3088/4885CA1 2239/4885 |
| US-20170202795-A1 | SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY | STAT3, STAT1, STAT5A | PTPN11 289/4885LCK 214/4885CA1 2965/4885 |
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | OPRL1, CNR1, TRPV1 | PTPN11 3427/4885LCK 2076/4885CA1 3196/4885 |
| US-20160304462-A1 | 3-SPIRO-7-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | HDAC7, HDAC6, HDAC1 | PTPN11 1171/4885LCK 532/4885CA1 1588/4885 |
| US-20140329900-A1 | SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY | STAT3, STAT1, JAK2 | PTPN11 163/4885LCK 239/4885CA1 2935/4885 |
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | PTPN11 2178/4885LCK 869/4885CA1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.